Prognostic Index for CLL
A number of biomarkers have been identified as being predictors of overall survival in chronic lymphocytic leukaemia (CLL). However, given that there are numerous biomarkers with inadequate information regarding their prognostic value
and limited knowledge on how to interpret them, they are not routinely used in clinical practice. In an effort to bring clarity and to develop a comprehensive prognostic index, an analysis was undertaken of 23 prognostic markers. The analysis was based on data gathered from phase III trials of the German CLL Study Group that involved 1,948 patients with CLL. Resulting from this analysis, a prognostic index for patients with CLL that identifies clinical, serum and molecular makers with independent prognostic values has been developed. For more information, click here.